A New Cancer Treatment Is On The Way—And Cancer Better Be Scared

A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis (NYSE:NVS) ground-breaking drug for pediatric and young adult B-cell acute lymphoblastic leukemia, or ALL. The recommendation clears the way for a formal FDA green light, and it begins a new era in the fight against cancer.

Back to news